Infectious Enteritis Treatment Market
Infectious Enteritis Treatment Market Size, Share & Trends Analysis Report by Treatment (Antibiotics, Antivirals, Antiparasitic Drugs, Oral Rehydration Therapy (ORT), Antidiarrheal Agents, Probiotics), by Infection (Bacterial Enteritis, Viral Enteritis, Parasitic Enteritis), by Route of Administration (Oral, Intravenous (IV)), and Forecast Period (2026–2035)
Industry Overview
Infectious enteritis treatment market was valued at approximately $529.2 million in 2025 and is expected to reach around $1,051.4 million by 2035, registering a CAGR of 7.2% during the forecast period from 2026 to 2035. Market growth is largely driven by the increasing global burden of gastrointestinal infections caused by bacteria, viruses, and parasites. Rising awareness regarding early diagnosis and timely treatment, along with improving healthcare infrastructure and access, is further accelerating demand. The need for effective treatment options such as antibiotics and oral rehydration therapy (ORT) remains particularly strong in developing regions where disease prevalence is high. Additionally, the growing adoption of probiotics and preventive care approaches is reshaping the treatment landscape. Pharmaceutical companies are actively expanding their product portfolios and strengthening their geographic presence to capture opportunities in emerging markets.
Recent developments by major industry players are indirectly supporting market expansion. In November 2024, Johnson & Johnson was ranked among the top five companies in the 2024 Access to Medicine Index, reflecting its efforts to improve healthcare access in underserved regions. The company has contributed significantly by donating billions of doses of treatments aimed at combating intestinal worm infections, which are closely associated with infectious enteritis-related conditions. Studies include late-stage developments targeting respiratory syncytial virus (RSV), alongside advancements in pneumococcal and HIV therapies. Such initiatives emphasize ongoing innovation in infectious disease management and indirectly contribute to strengthening the availability, accessibility, and effectiveness of treatments within the broader infectious enteritis treatment market.
Market Dynamics
Antibiotic Innovation Takes Center Stage in Combating Infectious Enteritis amid Rising AMR Threat
Antibiotics continue to dominate the infectious enteritis treatment market due to their proven efficacy in managing bacterial gastrointestinal infections. Both broad-spectrum and targeted antibiotic therapies remain the primary choice among clinicians globally. In March 2026, GlaxoSmithKline plc secured the top position in the Antimicrobial Resistance (AMR) Benchmark Report, highlighting its leadership in antibiotic and vaccine innovation. The company demonstrated the strongest pipeline of AMR-focused medicines, including advanced treatments targeting drug-resistant pathogens. This recognition underscores growing industry efforts to combat antimicrobial resistance, a major challenge in treating bacterial infections. Continuous development of next-generation antibiotics is enhancing therapeutic effectiveness and patient outcomes. These advancements are particularly significant for conditions such as bacterial enteritis, where timely and effective treatment is critical. Overall, innovation in antibiotic therapies is reinforcing market growth and improving global disease management strategies.
Fast-Track Therapies Fuel Growth in Bacterial Enteritis Treatment Market
Bacterial enteritis continues to command the largest share of the infectious enteritis treatment market, driven by its higher severity and the need for prompt medical intervention. Its widespread prevalence and risk of complications sustain consistent demand for effective therapies across healthcare systems. In April 2026, Sanofi S.A. emphasized the rising role of expedited drug approval pathways in accelerating patient access to innovative treatments. Regulatory bodies are increasingly adopting faster review frameworks, with approval timelines shrinking to nearly six months. This shift is particularly crucial for high-burden and serious infectious diseases. Faster approvals enable pharmaceutical companies to bring advanced gastrointestinal and anti-infective therapies to market more quickly. As a result, patients benefit from earlier access to improved treatment options. These regulatory advancements are playing a key role in strengthening the infectious enteritis treatment landscape.
Market Segmentation
- Based on treatment, the market is segmented into antibiotics, antivirals, antiparasitic drugs, oral rehydration therapy (ORT), antidiarrheal agents, and probiotics.
- Based on infection, the market is segmented into bacterial enteritis, viral enteritis, and parasitic enteritis.
- Based on route of administration, the market is segmented into oral and intravenous (IV).
Affordable Oral Therapies Take Center Stage: Expanding Access Drives Growth in Infectious Enteritis Treatment
Oral administration continues to dominate the infectious enteritis treatment market, driven by its convenience, cost-effectiveness, and ease of use. Patients prefer oral medications over injections or intravenous therapies, leading to higher treatment compliance and better outcomes. In February 2026, Pfizer Inc. introduced a cost-savings initiative through the TrumpRx platform to enhance affordability for U.S. patients. The program offers substantial discounts on more than 30 branded medicines via a direct-to-consumer model. This move aims to simplify access and reduce financial barriers to essential treatments. By improving availability of oral drugs, the initiative encourages wider adoption of patient-friendly therapies. It also aligns with broader efforts to lower prescription drug prices across the country. Such developments are expected to strengthen the role of oral treatments in managing infectious enteritis. Overall, increased affordability and accessibility are key factors accelerating market growth.
Regional Outlook
The global infectious enteritis treatment market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the leading region in the market
North America dominates the infectious enteritis treatment market due to its well-established healthcare infrastructure and high availability of pharmaceutical products. In December 2025, Merck & Co., Inc. announced a landmark agreement with the U.S. government aimed at improving access to medicines and reducing patient costs. The initiative includes a direct-to-patient distribution model that offers selected drugs at significantly lower prices, addressing affordability challenges. Additionally, the company committed to investing in domestic manufacturing capabilities and expanding its research and development efforts. These measures are expected to enhance drug supply and ensure consistent availability across the region. Improved affordability and accessibility are likely to encourage higher treatment adoption rates. The initiative also strengthens the overall healthcare ecosystem by supporting innovation and efficient delivery systems. As a result, this development reinforces North America’s leading position in the infectious enteritis treatment market.
Market Players Outlook
The major companies operating in the global infectious enteritis treatment market include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Bayer AG, and Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their business and drive innovative product development, maintaining their market positioning.
Recent Development
- In February 2026, Abbott Laboratories partnered with Novo Nordisk India to launch Extensior, a semaglutide-based therapy for advanced type 2 diabetes management. Under this collaboration, Abbott will commercialize the drug while Novo Nordisk supplies the molecule, widely known as Ozempic. The initiative aims to expand access to evidence-based GLP-1 therapies across India by leveraging Abbott’s distribution network. This development strengthens the companies’ presence in the metabolic and chronic disease treatment segment rather than infectious enteritis.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global infectious enteritis treatment market
- Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Infectious Enteritis Treatment Market Sales Analysis – Treatment| Infection| Route of Administration ($ Million)
- Infectious Enteritis Treatment Market Sales Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach Analytics
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Infectious Enteritis Treatment Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers of Infectious Enteritis Treatment Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Infectious Enteritis Treatment Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Infectious Enteritis Treatment Market Revenue and Share by Manufacturers
- Infectious Enteritis Treatment Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Merck
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bayer
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Infectious Enteritis Treatment Market Sales Analysis By Treatment ($ Million)
- Antibiotics
- Antivirals
- Antiparasitic Drugs
- Oral Rehydration Therapy (ORT)
- Antidiarrheal Agents
- Probiotics
- Infectious Enteritis Treatment Market Sales Analysis By Infection ($ Million)
- Bacterial Enteritis
- Viral Enteritis
- Parasitic Enteritis
- Infectious Enteritis Treatment Market Sales Analysis By Route of Administration ($ Million)
- Oral
- Intravenous (IV)
- Regional Analysis
- North American Infectious Enteritis Treatment Market Sales Analysis – Treatment | Infection | Route of Administration| Country ($ Million)
- United States
- Canada
- North American Infectious Enteritis Treatment Market Sales Analysis – Treatment | Infection | Route of Administration| Country ($ Million)
- European Infectious Enteritis Treatment Market Sales Analysis – Treatment| Infection | Route of Administration| Country ($ Million)
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Infectious Enteritis Treatment Market Sales Analysis – Treatment | Infection | Route of Administration| Country ($ Million)
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the Infectious Enteritis Treatment Market Sales Analysis – Treatment | Infection | Route of Administration| Country ($ Million)
- Latin America
- Middle East and Africa
- Company Profiles
- Abbott Laboratories
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alkem Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amneal Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aurobindo Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biocodex
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Glenmark Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mankind Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Merck & Co., Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Nestlé S.A. (Nestlé Health Science)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Procter & Gamble Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reckitt Benckiser Group plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Torrent Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Abbott Laboratories
1. Global Infectious Enteritis Treatment Market Research and Analysis By Treatment , 2025-2035 ($ Million)
2. Global Antibiotics Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Antivirals Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Antiparasitic Drugs Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
5. Global Oral Rehydration Therapy (ORT) Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
6. Global Antidiarrheal Agents Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
7. Global Probiotics Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
8. Global Infectious Enteritis Treatment Market Research and Analysis By Infection, 2025-2035 ($ Million)
9. Global Bacterial Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
10. Global Viral Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
11. Global Parasitic Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
12. Global Infectious Enteritis Treatment Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
13. Global Infectious Enteritis Treatment For Oral Market Research and Analysis By Region, 2025-2035 ($ Million)
14. Global Infectious Enteritis Treatment For Intravenous (IV) Market Research and Analysis By Region, 2025-2035 ($ Million)
15. Global Infectious Enteritis Treatment Global Infectious Enteritis Treatment Market Research and Analysis By Region, 2025-2035 ($ Million)
16. North American Infectious Enteritis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
17. North American Infectious Enteritis Treatment Market Research and Analysis By Treatment, 2025-2035 ($ Million)
18. North American Infectious Enteritis Treatment Market Research and Analysis By Infection, 2025-2035 ($ Million)
19. North American Infectious Enteritis Treatment Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
20. European Infectious Enteritis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
21. European Infectious Enteritis Treatment Market Research and Analysis By Treatment, 2025-2035 ($ Million)
22. European Infectious Enteritis Treatment Market Research and Analysis By Infection, 2025-2035 ($ Million)
23. European Infectious Enteritis Treatment Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
24. Asia-Pacific Infectious Enteritis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
25. Asia-Pacific Infectious Enteritis Treatment Market Research and Analysis By Treatment, 2025-2035 ($ Million)
26. Asia-Pacific Infectious Enteritis Treatment Market Research and Analysis By Infection, 2025-2035 ($ Million)
27. Asia-Pacific Infectious Enteritis Treatment Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
28. Rest of the World Infectious Enteritis Treatment Market Research and Analysis By Country, 2025-2035 ($ Million)
29. Rest of the World Infectious Enteritis Treatment Market Research and Analysis By Treatment, 2025-2035 ($ Million)
30. Rest of the World Infectious Enteritis Treatment Market Research and Analysis By Infection, 2025-2035 ($ Million)
31. Rest of the World Infectious Enteritis Treatment Market Research and Analysis By Route of Administration, 2025-2035 ($ Million)
1. Global Infectious Enteritis Treatment Market Research and Analysis By Treatment, 2025 Vs 2035 ($ Million)
2. Global Antibiotics Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
3. Global Antivirals Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
4. Global Antiparasitic Drugs Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
5. Global Oral Rehydration Therapy (ORT) Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
6. Global Antidiarrheal Agents Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
7. Global Probiotics Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
8. Global Infectious Enteritis Treatment Market Research and Analysis By Infection, 2025 Vs 2035 ($ Million)
9. Global Bacterial Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
10. Global Viral Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
11. Global Parasitic Infectious Enteritis Treatment Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
12. Global Infectious Enteritis Treatment Market Research and Analysis By Route of Administration, 2025 Vs 2035 ($ Million)
13. Global Infectious Enteritis Treatment For Oral Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
14. Global Infectious Enteritis Treatment For Intravenous (IV) Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
15. US Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
16. Canada Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
17. UK Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
18. France Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
19. Germany Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
20. Italy Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
21. Spain Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
22. Russia Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
23. Rest of Europe Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
24. India Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
25. China Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
26. Japan Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
27. South Korea Infectious Enteritis Treatment, 2025-2035 ($ Million)
28. Australia and New Zealand Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
29. ASEAN Economies INFECTIOUS ENTERITIS TREATMENT Market Size, 2025-2035 ($ Million)
30. Rest of Asia-Pacific Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
31. Latin America Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
32. Middle East and Africa Infectious Enteritis Treatment Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
